Encysted Papillary Carcinoma of the Breast (EPC): A Follow-up Study to Investigate the Role of Sentinel Lymph Node Biopsy

Ioannis Spyrou (1), Foivos Irakleidis (2), Stergios Douvetzemis (3), Hisham Hamed (4), Ashutosh Kothari (5)
(1) The Breast Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK, United Kingdom,
(2) The Breast Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK, United Kingdom,
(3) The Breast Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK, United Kingdom,
(4) The Breast Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK, United Kingdom,
(5) The Breast Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK, United Kingdom

Abstract

Background: Encysted papillary carcinoma (EPC) is a rare breast neoplasm that mainly affects postmenopausal women. The purpose of this study was to examine whether a sentinel node biopsy would be deemed necessary in patients with a diagnosis of EPC and to determine if evidence of invasiveness can be diagnosed on a core needle biopsy with sufficient confidence to guide decision making for upfront axillary SLNB.
Methods: The available data of patients with EPC of the breast were reviewed at a tertiary breast cancer unit over a period of 10 years (2009-2019) and the concordance between core needle biopsy and final histology was assessed. We also carried out a detailed review of the available literature to inform best practice guidance for management of the axilla.
Results: During the study, a total of 37 EPC patients were identified, of whom 10 were excluded as they declined further treatment, providing us a study sample of 27 patients. The median age at diagnosis was 72 years (range 47-97) and the vast majority of patients (96%) were Estrogen Receptor (ER) positive. Of the 27 patients treated, 17 (63%) underwent a diagnostic axillary Sentinel Lymph Node Biopsy (SLNB). On the final histology, 13/27 (48%) proved to have invasive disease. A total of 5 (18%) patients had evidence of metastasis in the axillary nodes, of whom only 7% had macro-metastatic disease that warranted further axillary treatment. None of the treated patients had evidence of recurrence or distant metastatic disease, to date (median of 5 years of follow up).
Conclusions: Encysted papillary carcinoma is associated with a low incidence of axillary node involvement. SLNB should only be carried out when there is evidence of invasive cancer. An algorithm was developed to help guide management of the axilla in cases diagnosed with EPC on diagnostic core needle biopsy.

Full text article

Generated from XML file

References

Mulligan AM, O'Malley FP. Papillary lesions of the breast: a review. Adv Anat Pathol. 2007;14(2):108-19.

Solorzano CC, Middleton LP, Hunt KK, Mirza N, Meric F, et al. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002;184(4):364-8.

Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology. 2008;52(1):20-9.

Esposito NN, Dabbs DJ, Bhargava R. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases. Am J Clin Pathol. 2009;131(2):228-42.

Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol. 2005;123(1):36-44.

Wei S. Papillary Lesions of the Breast: An Update. Arch Pathol Lab Med. 2016;140(7):628-43.

Liberman L, Feng TL, Susnik B. Case 35: intracystic papillary carcinoma with invasion. Radiology. 2001;219(3):781-4.

Eiada R, Chong J, Kulkarni S, Goldberg F, Muradali D. Papillary lesions of the breast: MRI, ultrasound, and mammographic appearances. AJR Am J Roentgenol. 2012;198(2):264-71.

Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol. 1994;25(8):802-9.

Stamatakos M, Stefanaki C, Stasinou T, Papantoni E, Alexiou I, et al. Intracystic Papillary Carcinoma of the Breast in Males. In Search of the Optimal Treatment for this Rare Disease. Breast Care (Basel). 2011;6(5):399-403.

Mogal H, Brown DR, Isom S, Griffith K, Howard-McNatt M. Intracystic papillary carcinoma of the breast: A SEER database analysis of implications for therapy. Breast. 2016;27:87-92.

Rakha EA, Gandhi N, Climent F, van Deurzen CH, Haider SA, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol. 2011;35(8):1093-103.

Grabowski J, Salzstein SL, Sadler GR, Blair S. Intracystic papillary carcinoma: a review of 917 cases. Cancer. 2008;113(5):916-20.

J. Kratz SP, N. Barnes Manchester Royal Infirmary, Central Manchester University Hospitals,Adult Histopathology Dept., United Kingdom, 2017.

Wang Y, Lu S, Graves T, Ouseph MM, Resnick MB, et al. Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast? Clin Breast Cancer. 2017;17(2):127-33.

Authors

Ioannis Spyrou
yannos_s@hotmail.com (Primary Contact)
Foivos Irakleidis
Stergios Douvetzemis
Hisham Hamed
Ashutosh Kothari
1.
Spyrou I, Irakleidis F, Douvetzemis S, Hamed H, Kothari A. Encysted Papillary Carcinoma of the Breast (EPC): A Follow-up Study to Investigate the Role of Sentinel Lymph Node Biopsy . Arch Breast Cancer [Internet]. 2020 Nov. 16 [cited 2024 Aug. 31];:178-82. Available from: https://archbreastcancer.com/index.php/abc/article/view/316

Article Details